Easton Pharmaceuticals Announces Mr. Kent Deuters as Chief Operations Officer & Special Advisor on the Company's Medical Mari...
April 03 2014 - 11:04AM
Marketwired
Easton Pharmaceuticals Announces Mr. Kent Deuters as Chief
Operations Officer and Special Advisor on the Company's Medical
Marijuana Initiatives and Other Company Business Segments; Provides
Further Updates on Its Medical Marijuana Program
TORONTO, ON--(Marketwired - Apr 3, 2014) - Easton
Pharmaceuticals Inc. (OTC: EAPH) announces the appointment of Mr.
Kent A. Deuters to the position of Chief Operations Officer and
Special Advisor.
Kent Deuters adds 20 years of financial banking, payment
processing, branding, food industry and medical marijuana
expertise. He has structured and developed business plans, patient
acquisition strategies and operating procedures for several
companies in the medical marijuana industry in both Canada and the
United States. Mr. Deuters has an extensive well respected business
background in both large and small international companies and
highly experienced in business development. Easton Pharmaceuticals
is aggressively looking to identify a diverse cross section of
opportunities that will deliver shareholders accelerated growth and
the substantial revenue streams. Kent Deuters is developing
tactical business partnerships and joint ventures in the
$900,000,000 per anum Colorado marijuana market and is seeking
early entry into Washington, Oregon and other soon to be licensed
states. Easton's pharmaceutical's industry experience will also
allow them to develop alternate delivery systems for medicinal
users on top of our Viorra and other brand of products through the
assistance of BMV Medica in Mexico.
Kent has been brought on board specifically in the short term,
to quickly evaluate all medical marijuana proposals Easton
Pharmaceuticals has maintained, which has grown and presently
involves negotiations with 4 companies or groups in Canada and one
in Colorado. These include negotiations with a well established
grower in British Columbia that has recently forwarded a
revised proposal to Easton for review, an Ontario company that
has filed for a well detailed growers application in Ontario, which
includes privately owned growing facilities and discussions for a
partnership to create or acquire a slew of medical marijuana
companies and assets within Canada. In addition to the Canadian
medical marijuana initiatives is a Letter Of Intent that was signed
for a partnership for a proposed acquisition of a current grower in
the State of Colorado which the company's attorney has been
currently reviewing and performing due diligence on. Mr.
Deuters has received approval from Easton to travel to Colorado in
the coming days to make an introduction to Easton Pharmaceuticals
with contacts he has earned close relationships with in the medical
marijuana industry who are current growers and in search of
partners and expansion financing. Easton Pharmaceuticals has
recently been successful at raising some financing. The company
would like to close on medical marijuana initiatives in both Canada
and the United States, which is conceivable if the company receives
its additional committed financing as previously announced. The
company is in the final stages of drafting and filing a
registration statement for the purpose of raising up to
$5,000,000.
Kent Deuters, commented, "I am thrilled to be working with
Easton Pharmaceuticals in this remarkable space that is only in its
infancy stage," Deuters further commented. "Opportunities abound
for a company like Easton in the US market. We want to establish
ourselves as a major player, and I believe we are primed for huge
expansion and growth."
In Canada, health Canada estimates that the current legal users
of medical marijuana will grow from its current level of 30,000
users to over 400,000 by the year 2020. If Marijuana is legalized
for recreational use as in Colorado and other states, this number
will grow exponentially. The market in Colorado is already unable
to meet demand since being legalized for recreational use in early
January of this year. Other states are anticipated to follow the
lead from Colorado which could pave the way for the
decriminalization of marijuana use by the Unites States federal
government.
Safe Harbor This news release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (The "Act"). In particular, when used in the
preceding of discussion, the words "anticipate," "pleased," "plan,"
"confident that," "believe," "expect," "possible" or "intent to"
and similar conditional expressions are intended to identify
forward-looking statements within the meaning of the Act and are
subject to the safe harbor created by the Act. Such statements are
subject to certain risks and uncertainties and actual results could
differ materially from those expressed in any of the
forward-looking statements. There are no guarantees or assurances
that any proposals, initiatives or negotiations will result in a
deal acceptable to the company. Any investment made into Easton
Pharmaceuticals would be classified as speculative and risky. Such
risks and uncertainties include, but are not limited to, market
conditions, general acceptance of the company's products and
technologies, competitive factors, the ability to successfully
complete additional or adequate financing, government approvals or
changes to proposed laws and other risks and uncertainties further
stated in the company's financial reports and filings.
Contact: Carla Pepe Easton Pharmaceuticals Inc. Tel: +1(416)
619-0291 Tel: +1(347) 284-0192 info@eastonpharmaceuticalsinc.com
kdeuters@eastonpharmaceuticalsinc.com
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Sep 2023 to Sep 2024